Wednesday, July 12, 2023
Metabion, a renowned oligonucleotide solutions provider, has recently increased its global production capacity for diagnostic and therapeutic oligonucleotides and their derivatives. This expansion is a response to the growing demand in Europe and worldwide. Over the past couple of years, the company has invested in the construction and establishment of a state-of-the-art manufacturing facility dedicated to producing oligonucleotide components at various scales. These components are used in applications such as in vitro diagnostics (IVD)/analyte-specific reagents (ASRs), research and development (R&D), and therapeutics.
The investment, amounting to a significant double-digit million EURO amount, includes the creation of ISO 8 and 7 classified clean room areas. Metabion adheres to certified standards such as ISO 9001:2015, ISO 13485:2016, and EXCiPACT® GMP/GDP:2021.
Dr. Regina Bichlmaier, CEO of metabion, expresses the company's commitment to strengthen its contract manufacturing organization (CMO) segment and expand its business in this field. Additionally, the investment aims to address the increasing demand for customized diagnostic solutions, including packaging, kitting, and original equipment manufacturer (OEM) services. Metabion also aims to support early-stage oligonucleotide-based drug development, spanning lead discovery and optimization to pre-clinical development and clinical phases I and II. Dr. Bichlmaier emphasizes the outstanding capabilities of the newly established production site located in the eastern part of Munich, highlighting metabion's dedication to providing exceptional expertise, capacity, customization, and flexibility to fulfill diverse oligonucleotide requirements.
Dr. Heike Koepf, Head of Sales and Quality Management, underscores metabion's commitment to drive growth in the custom oligonucleotide business by maintaining a strong customer focus. Through intensified collaborations with European customers and an expanded product portfolio, metabion aims to cater to the needs of interested parties worldwide.
